Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
April 23 2024 - 7:00AM
Business Wire
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a
clinical-stage biotechnology company developing a new generation of
targeted immunotherapies, is pleased to invite investors to a
webinar on April 24, 2024 at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature
Calidi Biotherapeutics Chief Business Officer, Stephen Thesing,
Chief Scientific Officer, Antonio F. Santidrian, Ph.D., and Chief
Financial Officer, Andrew Jackson, who will share insight into the
Company’s proprietary technology platforms and current development
pipeline. A live Q&A session will follow the presentation.
To register for the free webinar, please visit:
https://redchip.zoom.us/webinar/register/WN_qT-PBRbTQ0yLeBbJ4jzPSw#/registration
Questions can be pre-submitted to CLDI@redchip.com or online
during the live event.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage
immuno-oncology company with proprietary technology designed to arm
the immune system to fight cancer. Calidi’s novel stem cell-based
platforms are utilizing potent allogeneic stem cells capable of
carrying payloads of oncolytic viruses for use in multiple oncology
indications, including high-grade gliomas and solid tumors.
Calidi’s clinical stage off-the-shelf, universal cell-based
delivery platforms are designed to protect, amplify, and potentiate
oncolytic viruses leading to enhanced efficacy and improved patient
safety. Calidi’s preclinical off-the-shelf enveloped virotherapies
are designed to target disseminated solid tumors. This dual
approach can potentially treat, or even prevent, metastatic
disease. Calidi Biotherapeutics is headquartered in San Diego,
California. For more information, please visit
www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for
purposes of the "safe harbor" provisions under the United States
Private Securities Litigation Reform Act of 1995. Terms such as
"anticipates," "believe," "continue," "could," "estimate,"
"expect," "intends," "may," "might," "plan," "possible,"
"potential," "predicts," "project," "should," "towards," "would" as
well as similar terms, are forward-looking in nature, but the
absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include, but are
not limited to, statements concerning upcoming key milestones
(including the reporting of interim clinical results and the dosing
of patients), planned clinical trials, and statements relating to
the safety and efficacy of Calidi’s therapeutic candidates in
development. Any forward-looking statements contained in this
discussion are based on Calidi’s current expectations and beliefs
concerning future developments and their potential effects and are
subject to multiple risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth or
implied in such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that Calidi
is not able to raise sufficient capital to support its current and
anticipated clinical trials, the risk that early results of
clinical trials do not necessarily predict final results and that
one or more of the clinical outcomes may materially change
following more comprehensive review of the data, and as more
patient data becomes available, the risk that Calidi may not
receive FDA approval for some or all of its therapeutic candidates.
Other risks and uncertainties are set forth in the section entitled
"Risk Factors" and "Cautionary Note Regarding Forward-Looking
Statements" in the Company’s Form 10-K filed on March 15, 2024 and
Final Prospectus filed on April 17, 2024.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240423753116/en/
Dave Gentry RedChip Companies, Inc. 1-407-644-4256
CLDI@redchip.com
Stephen Thesing Calidi Biotherapeutics, Inc. 1-858-794-9603
ir@calidibio.com
Calidi Biotherapeutics (AMEX:CLDI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Calidi Biotherapeutics (AMEX:CLDI)
Historical Stock Chart
From Aug 2023 to Aug 2024